FDA Approves Amgen’s UPLIZNA(R) (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
FDA Approves Amgen's UPLIZNA(R) (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease GlobeNewswire December 12, 2025 New York, Dec. 12, 2025 (GLOBE NEWSWIRE) — The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized […]